<DOC>
	<DOCNO>NCT00210717</DOCNO>
	<brief_summary>The purpose study compare effectiveness safety 1 year treatment intramuscular injection paliperidone palmitate long-acting risperidone patient schizophrenia .</brief_summary>
	<brief_title>A Study Compare Effectiveness Safety Flexibly Varied Doses Paliperidone Palmitate Risperidone Treating Patients With Schizophrenia</brief_title>
	<detailed_description>Paliperidone palmitate develop long-acting intramuscular injectable formulation treatment schizophrenia . Many patient schizophrenia achieve symptom stability available oral antipsychotic medication ; however , estimate 75 % difficulty adhere daily oral treatment regimen . Long-acting injectable formulation may make compliance treatment regimen easier eliminate need daily medication . An injectable formulation risperidone widely use treatment schizophrenia well tolerated patient chronic schizophrenia recommend dosage 25 50 milligram every 2 week . The present study design evaluate comparability paliperidone palmitate long-acting injectable risperidone 1 year treatment . This randomized , double-blind , active-controlled , parallel-group , multicenter comparative study patient schizophrenia . The study comprise screen period 1 week ( include period washout psychotropic medication , necessary , oral tolerability test ) 53-week double-blind treatment period . In double-blind treatment period , patient randomly assign equal number receive treatment either ( 1 ) flexibly dose paliperidone palmitate administer every 4 week ( 2 ) flexibly dose long-acting risperidone administer every 2 week . Drug effectiveness safety evaluate periodically throughout study . Samples pharmacokinetic evaluation collect designated time point , blood sample collect baseline ( start double-blind treatment period ) subsequent visit optional pharmacogenomic ( genetic ) analysis . The study hypothesis paliperidone palmitate effective long-acting risperidone treatment patient schizophrenia . Paliperidone palmitate ( 25 , 50 , 75 , 100 milligram ( mg ) equivalent ) every 4 week , long-acting risperidone 25 , 37.5 , 50 mg every 2 week double-blind treatment period , injected gluteal muscle ( buttock ) . Oral risperidone ( 1-6 mg ) first 4 week double-blind period</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>A diagnosis schizophrenia ( disorganize , catatonic , paranoid , residual , undifferentiated type ) accord Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSM IV ) least 1 year screen evaluation total PANSS score 60 120 screening baseline ( pretreatment ) evaluation body mass index ( BMI [ weight ( kilogram ) ] / [ height ( meter ) ] ² ) least 15.0 kg/m² . A primary active DSMIV Axis I diagnosis schizophrenia decrease 25 % total PANSS score screen baseline evaluation DSMIV diagnosis active substance dependence within 3 month screen evaluation history treatment resistance define failure respond 2 adequate trial different antipsychotic medication woman pregnant , breastfeeding , plan become pregnant study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>intramuscular injection</keyword>
	<keyword>antipsychotic agent</keyword>
	<keyword>risperidone</keyword>
	<keyword>paliperidone palmitate</keyword>
	<keyword>dementia praecox</keyword>
	<keyword>mental disorder</keyword>
	<keyword>PANSS</keyword>
</DOC>